Adicet Bio (ACET) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 17, 2026, with voting available online or virtually.
Shareholders are encouraged to review proxy materials and vote by June 16, 2026.
Voting matters and shareholder proposals
Election of three class II directors for a three-year term ending at the 2029 annual meeting.
Advisory vote to ratify executive compensation for named executive officers.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Nominees for director positions include Jeffrey Chodakewitz, M.D., Steve Dubin, J.D., and Michael Grissinger.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Adicet Bio
- All proposals, including director elections and auditor ratification, were approved by stockholders.ACET
AGM 202617 Jun 2026 - Major mid-year data update for prula-cel in autoimmune diseases and new solid tumor program advancing.ACET
Jefferies Global Healthcare Conference 20264 Jun 2026 - Net loss narrowed, cash runway extends into H2 2027 as pivotal trials advance and risks persist.ACET
Q1 202613 May 2026 - Prula-cel delivers durable remission and immune reset in autoimmune disease, while ADI-212 advances for mCRPC.ACET
Investor presentation13 May 2026 - Virtual annual meeting to elect directors, approve pay, and ratify auditor, with robust governance.ACET
Proxy filing29 Apr 2026 - Prula-cel delivers steroid-free remissions and immune reset in autoimmune disease patients.ACET
Investor presentation12 Mar 2026 - Biotech seeks up to $250M for cell therapy pipeline, targeting autoimmune and cancer markets.ACET
Registration Filing12 Mar 2026 - Clinical pipeline advances and solid cash position support continued execution into 2027.ACET
Q4 202512 Mar 2026 - Allogeneic Gamma-delta CAR-T therapies advance in autoimmune trials, with initial data imminent.ACET
Canaccord Genuity’s 45th Annual Growth Conference3 Feb 2026